Memantinol

Asset

Uncompetitive NMDA receptor antagonist protecting against glutamate-induced excitotoxicity

Stage: Phase 1
Modality: Small molecule
Target: GRIN2B; 1
Indication: 142
Trials: 1
Developer

Indications

1

Bioequivalence auc cmax pharmacokinetic
Phase 1, Completed, NCT03121820, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Trials142
Evidence for its targets4
Competitors3
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.